Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Get Free Report) Director Michael Andrew Holloway acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 18th. The shares were acquired at an average price of $2.82 per share, with a total value of $42,300.00. Following the acquisition, the director owned 55,000 shares in the company, valued at approximately $155,100. The trade was a 37.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Lixte Biotechnology Price Performance
Lixte Biotechnology stock opened at $2.26 on Friday. The stock has a market capitalization of $36.39 million, a PE ratio of -1.60 and a beta of 1.37. Lixte Biotechnology Holdings, Inc. has a 12 month low of $2.15 and a 12 month high of $8.38. The business has a 50 day simple moving average of $3.67 and a 200-day simple moving average of $4.64.
Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.74) earnings per share for the quarter. The company had revenue of $0.47 million for the quarter.
Institutional Trading of Lixte Biotechnology
A number of hedge funds have recently made changes to their positions in the business. Equitable Holdings Inc. bought a new position in shares of Lixte Biotechnology in the 2nd quarter valued at $74,000. FNY Investment Advisers LLC purchased a new stake in Lixte Biotechnology during the second quarter worth about $330,000. BlackRock Inc. bought a new position in Lixte Biotechnology in the 2nd quarter worth approximately $564,000. Finally, Legacy Wealth Managment LLC ID bought a new position in shares of Lixte Biotechnology during the 2nd quarter valued at about $4,457,000. 5.10% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
View Our Latest Research Report on Lixte Biotechnology
About Lixte Biotechnology
Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.
Read More
- Five stocks we like better than Lixte Biotechnology
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
